MarketCap
Facebook
X
Telegram
PerkinElmer Accounts Payables | PKI
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 185 M | 167 M | 204 M | 325 M | 327 M | - | 236 M | 221 M | 222 M | 153 M | - | 174 M | 167 M | 169 M | 161 M | 134 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 327 M | 134 M | 203 M |
Quarterly Accounts Payables PerkinElmer
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 185 M | 170 M | 167 M | 176 M | 178 M | 178 M | 167 M | 176 M | 175 M | 184 M | 204 M | 188 M | 236 M | 267 M | 273 M | 276 M | 334 M | 377 M | 327 M | 320 M | 325 M | 339 M | - | 258 M | 255 M | 233 M | 236 M | 236 M | 236 M | 236 M | 221 M | 221 M | 221 M | 221 M | 222 M | 222 M | 222 M | 222 M | 141 M | 162 M | 156 M | 159 M | - | 150 M | 171 M | 157 M | 174 M | 174 M | 174 M | 174 M | 167 M | 167 M | 167 M | 167 M | 169 M | 169 M | 169 M | 169 M | 161 M | 151 M | 149 M | 149 M | 134 M | 143 M | 175 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 377 M | 134 M | 204 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
377 K | $ 1.61 | -1.55 % | $ 4.69 M |  USA |
 |
Interpace Biosciences
IDXG
|
983 K | $ 7.0 | -13.43 % | $ 31 M | USA |
 |
ICON Public Limited Company
ICLR
|
192 M | $ 204.67 | 1.5 % | $ 16.1 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
1.88 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
40.7 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
DarioHealth Corp.
DRIO
|
2.93 M | $ 2.4 | -11.93 % | $ 9.56 M |  Israel |
 |
Myriad Genetics
MYGN
|
30 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
383 K | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
23.1 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
41.1 M | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
20.8 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
79.1 M | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
1.13 M | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
13 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
78 M | $ 16.01 | 0.88 % | $ 4.55 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | China |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Check-Cap Ltd.
CHEK
|
790 K | - | - | $ 9.42 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
1.17 M | $ 25.62 | 0.55 % | $ 573 M | USA |
 |
Twist Bioscience Corporation
TWST
|
11.1 M | $ 120.83 | 0.18 % | $ 7.23 B | USA |
 |
Organovo Holdings
ONVO
|
1.02 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
1.08 M | - | -16.95 % | $ 1.54 M | USA |
 |
Soleno Therapeutics
SLNO
|
12.4 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
307 M | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
1.84 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
110 M | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
240 M | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
42.9 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
4.84 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
28.1 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
267 M | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
33.2 M | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
149 M | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
72.7 M | $ 50.36 | -0.98 % | $ 10.9 B |  Niderland |
 |
RadNet
RDNT
|
153 M | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
4.06 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
1.53 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
10.7 M | $ 2.17 | -10.91 % | $ 143 M | USA |